Literature DB >> 21779207

The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma.

Peter Hellstern1, Bjarte G Solheim.   

Abstract

The solvent/detergent (SD) process used for plasma can safely inactivate all lipid-enveloped viruses. The introduction of a specific prion-binding ligand gel in combination with SD treatment, time-reduced from 4 to 1-1.5 h, still ensures efficient virus kill, reduces abnormal prion protein by >5 log steps, and preserves levels of plasmin inhibitor at close to the reference range. Infections with known non-enveloped viruses such as HAV or parvovirus B19 are prevented by ensuring low virus loads in the starting plasma units, dilution through pooling of single plasma units, and neutralization of immune antibodies already present in the initial plasma pools. The major advantages of SD plasma over fresh frozen plasma and the other pathogen-inactivated plasmas are its extreme safety with respect to transfusion-related acute lung injury and the significantly lower likelihood of provoking allergic reactions. Both advantages are best interpreted as results of the dilution effect of pooling. No fewer than 18 clinical studies covering all indications for plasma, and extensive clinical experience have shown that reduced levels of coagulation factors and inhibitors as a result of SD treatment do not impair significantly the clinical efficacy or tolerance of plasma. Properly standardized clotting factor and inhibitor potencies and low batch-to-batch variations when compared with single-donor plasma units makes SD plasma more suitable for standardized treatment.

Entities:  

Year:  2011        PMID: 21779207      PMCID: PMC3132981          DOI: 10.1159/000323552

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  28 in total

1.  Composition, efficacy, and safety of S/D-treated plasma.

Authors:  Bjarte G Solheim; Peter Hellstern
Journal:  Transfusion       Date:  2003-08       Impact factor: 3.157

2.  Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas).

Authors:  P Sinnott; S Bodger; A Gupta; M Brophy
Journal:  Eur J Immunogenet       Date:  2004-12

Review 3.  Solvent/detergent-treated plasma: composition, efficacy, and safety.

Authors:  Peter Hellstern
Journal:  Curr Opin Hematol       Date:  2004-09       Impact factor: 3.284

Review 4.  Recommendations for the use of therapeutic plasma.

Authors:  Marcell Ulrich Heim; Britta Meyer; Peter Hellstern
Journal:  Curr Vasc Pharmacol       Date:  2009-04       Impact factor: 2.719

Review 5.  Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma.

Authors:  B Horowitz; A Lazo; H Grossberg; G Page; A Lippin; G Swan
Journal:  Vox Sang       Date:  1998       Impact factor: 2.144

6.  Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment.

Authors:  Tor-Einar Svae; Andrea Neisser-Svae; Andrew Bailey; Herwig Reichl; Lothar Biesert; Torben Schmidt; Andrea Heger; Jürgen Römisch
Journal:  Transfus Apher Sci       Date:  2008-07-10       Impact factor: 1.764

7.  Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma.

Authors:  B Horowitz; R Bonomo; A M Prince; S N Chin; B Brotman; R W Shulman
Journal:  Blood       Date:  1992-02-01       Impact factor: 22.113

8.  Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG.

Authors:  A Neisser-Svae; A Bailey; L Gregori; A Heger; S Jordan; M Behizad; H Reichl; J Römisch; T-E Svae
Journal:  Vox Sang       Date:  2009-06-22       Impact factor: 2.144

9.  Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.

Authors:  A M Prince; B Horowitz; B Brotman
Journal:  Lancet       Date:  1986-03-29       Impact factor: 79.321

Review 10.  Pathogen inactivation techniques.

Authors:  J P R Pelletier; S Transue; E L Snyder
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

View more
  37 in total

1.  West nile virus.

Authors:  Georg Pauli; Ursula Bauerfeind; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen
Journal:  Transfus Med Hemother       Date:  2013-07-04       Impact factor: 3.747

2.  Pathogen Reduction in Blood Products: What's Behind These Techniques?

Authors:  Karin Janetzko; Peter Bugert
Journal:  Transfus Med Hemother       Date:  2011       Impact factor: 3.747

3.  Usutu virus.

Authors:  Georg Pauli; Ursula Bauerfeind; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Ruth Offergeld; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen
Journal:  Transfus Med Hemother       Date:  2013-12-23       Impact factor: 3.747

Review 4.  Is solvent/detergent plasma better than standard fresh-frozen plasma? A systematic review and an expert consensus document.

Authors:  Marco Marietta; Massimo Franchini; M Lucia Bindi; Francesco Picardi; Matteo Ruggeri; Giustina De Silvestro
Journal:  Blood Transfus       Date:  2016-02-17       Impact factor: 3.443

Review 5.  Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Authors:  Americo Cicchetti; Alexandra Berrino; Marina Casini; Paola Codella; Giuseppina Facco; Alessandra Fiore; Giuseppe Marano; Marco Marchetti; Emanuela Midolo; Roberta Minacori; Pietro Refolo; Federica Romano; Matteo Ruggeri; Dario Sacchini; Antonio G Spagnolo; Irene Urbina; Stefania Vaglio; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2016-07       Impact factor: 3.443

6.  MPLEx: a method for simultaneous pathogen inactivation and extraction of samples for multi-omics profiling.

Authors:  Kristin E Burnum-Johnson; Jennifer E Kyle; Amie J Eisfeld; Cameron P Casey; Kelly G Stratton; Juan F Gonzalez; Fabien Habyarimana; Nicholas M Negretti; Amy C Sims; Sadhana Chauhan; Larissa B Thackray; Peter J Halfmann; Kevin B Walters; Young-Mo Kim; Erika M Zink; Carrie D Nicora; Karl K Weitz; Bobbie-Jo M Webb-Robertson; Ernesto S Nakayasu; Brian Ahmer; Michael E Konkel; Vladimir Motin; Ralph S Baric; Michael S Diamond; Yoshihiro Kawaoka; Katrina M Waters; Richard D Smith; Thomas O Metz
Journal:  Analyst       Date:  2017-01-26       Impact factor: 4.616

7.  Low incidence of hyperfibrinolysis and thromboembolism in 195 primary liver transplantations transfused with solvent/detergent-treated plasma.

Authors:  Håkon Haugaa; Eli Taraldsrud; Hans Christian Nyrerød; Tor Inge Tønnessen; Aksel Foss; Bjarte G Solheim
Journal:  Clin Med Res       Date:  2014-01-10

8.  Trauma hemostasis and oxygenation research position paper on remote damage control resuscitation: definitions, current practice, and knowledge gaps.

Authors:  Donald H Jenkins; Joseph F Rappold; John F Badloe; Olle Berséus; Lorne Blackbourne; Karim H Brohi; Frank K Butler; Andrew P Cap; Mitchell Jay Cohen; Ross Davenport; Marc DePasquale; Heidi Doughty; Elon Glassberg; Tor Hervig; Timothy J Hooper; Rosemary Kozar; Marc Maegele; Ernest E Moore; Alan Murdock; Paul M Ness; Shibani Pati; Todd Rasmussen; Anne Sailliol; Martin A Schreiber; Geir Arne Sunde; Leo M G van de Watering; Kevin R Ward; Richard B Weiskopf; Nathan J White; Geir Strandenes; Philip C Spinella
Journal:  Shock       Date:  2014-05       Impact factor: 3.454

9.  Rationale and mechanism for the low photoinactivation rate of bacteria in plasma.

Authors:  Jie Chen; Thomas C Cesario; Peter M Rentzepis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-24       Impact factor: 11.205

10.  Pulmonary complications of transfused blood components.

Authors:  Alexander B Benson
Journal:  Crit Care Nurs Clin North Am       Date:  2012-09       Impact factor: 1.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.